Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $6.9 million.

  • Anika Therapeutics' Depreciation & Amortization (CF) fell 25.22% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 19.25%. This contributed to the annual value of $6.9 million for FY2024, which is 6.99% up from last year.
  • Latest data reveals that Anika Therapeutics reported Depreciation & Amortization (CF) of $6.9 million as of FY2024, which was up 6.99% from $6.4 million recorded in FY2023.
  • Anika Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $6.9 million during FY2024, with a 5-year trough of $6.1 million in FY2020.
  • For the 3-year period, Anika Therapeutics' Depreciation & Amortization (CF) averaged around $6.7 million, with its median value being $6.7 million (2022).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first grew by 22.72% in 2020, then dropped by 4.03% in 2023.
  • Over the past 5 years, Anika Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $6.1 million in 2020, then climbed by 6.53% to $6.5 million in 2021, then climbed by 3.46% to $6.7 million in 2022, then decreased by 4.03% to $6.4 million in 2023, then increased by 6.99% to $6.9 million in 2024.